Description

Tresiba Flextatch (insulin degludec) solution for injections 100 IU/ml. 3 ml. №5 syringe

Ingredients:

Tresiba Flextatch contains insulin degludec as the active ingredient. Other ingredients include glycerol, metacresol, phenol, zinc, and water for injections.

Dosage:

The dosage of Tresiba Flextatch should be individualized based on the patient’s needs. It is typically injected subcutaneously once daily at any time of the day, but it should be administered at the same time each day.

Indications:

Tresiba Flextatch is indicated for the treatment of diabetes mellitus in adults, adolescents, and children aged 1 year and above.

Contraindications:

Tresiba Flextatch is contraindicated in patients with hypersensitivity to insulin degludec or any of the excipients in the formulation.

Directions:

Tresiba Flextatch should be administered subcutaneously into the thigh, upper arm, or abdomen. The injection site and timing should be rotated to reduce the risk of lipodystrophy.

Scientific Evidence:

Studies have shown that Tresiba Flextatch provides effective glycemic control with a lower risk of hypoglycemia compared to other long-acting insulins. Research published in the New England Journal of Medicine demonstrated its non-inferiority to insulin glargine in reducing HbA1c levels in patients with type 2 diabetes.

Additional Information:

Tresiba Flextatch offers a flexible dosing schedule and a long duration of action, making it a convenient option for patients requiring basal insulin therapy. It has been well-tolerated in clinical trials, with common side effects including hypoglycemia and injection site reactions.

Pharmacologically, insulin degludec in Tresiba Flextatch forms multi-hexamers upon subcutaneous injection, resulting in a depot of soluble multi-hexamer chains. This slow and continuous release of insulin provides a stable and prolonged glucose-lowering effect.

Compared to other long-acting insulins, Tresiba Flextatch has demonstrated a longer duration of action and a more consistent glucose-lowering effect, allowing for once-daily dosing in most patients. Clinical trials have shown its efficacy in reducing both fasting and postprandial glucose levels, leading to improved overall glycemic control.